Decitabine treatment of patients with higher-risk myelodysplastic syndromes
- 31 December 2009
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 33, S12-S17
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Assessment of ATRX expression in patients with myelodysplastic syndromes treated with decitabineLeukemia Research, 2009
- Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7Blood, 2009
- Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell linesBlood, 2009
- p53-Inducible Ribonucleotide Reductase (p53R2/RRM2B) Is a DNA Hypomethylation–Independent Decitabine Gene Target That Correlates with Clinical Response in Myelodysplastic Syndrome/Acute Myelogenous LeukemiaCancer Research, 2008
- Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7Blood, 2007
- Response: Decitabine response with chromosome 7 abnormality in MDS, and decitabine optimal scheduleBlood, 2007
- Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemiaCancer, 2007
- Monocytic skin nodules in chronic myelomonocytic leukemia: Clinical response to decitabine therapyLeukemia & Lymphoma, 2007
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood, 2006
- Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 2006